Article

Response to immune checkpoint inhibitor combined therapies in metastatic BRAF mutant lung cancers

2022-04-15

Abstract excerpt

The efficacy of immune checkpoint inhibitors (ICIs) combination regimens in BRAF mutant non-small cell lung cancers (NSCLCs) remains poorly explored. Immunotypes, including programmed death-ligand 1 (PD-L1) levels and tumor mutation burden (TMB), were evaluated. Objective response rate (ORR), disease control rate, progression-free survival (PFS), and overall survival (OS) of patients treated with ICI combination t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 21907330-f62f-5959-b095-98c08c56bcc3
DOI: 10.21203/rs.3.rs-1551063/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Response to immune checkpoint inhibitor combined therapies in metastatic BRAF mutant lung cancersDOI 10.21203/rs.3.rs-1551063/v1Read

Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.Semantic proximity Read

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.Semantic proximity Read

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity Read

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.Semantic proximity Read

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLCSemantic proximity Read

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.Semantic proximity Read

Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best ChoicesSemantic proximity Read

Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysisSemantic proximity Read

Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review.Semantic proximity Read

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLCSemantic proximity Read

[Application of Immune Checkpoint Inhibitors in EGFR Mutant Advanced Non-small Cell Lung Cancer].Semantic proximity Read